Evaluation of the efficacy of stem cell therapy in erectile dysfunction after radical prostatectomy: a comprehensive systematic review

Around 68% patients undergoing radical prostatectomy face postoperative erectile dysfunction. This systematic review aims to investigate the studies pertaining to efficacy of stem cell therapy in alleviating erectile dysfunction (ED) of radical prostatectomy (RP) patients. Furthermore, it provides evidence-based potential benefits of stem cell therapy in addressing erectile dysfunction of those patients. A systematic literature search from PubMed, Google Scholar, Science Direct and clinicaltrial.gov databases was conducted for the clinical trials evaluating efficacy and safety of stem cell therapy in post-prostatectomy erectile dysfunction. The inclusion criteria pertained to the studies reporting pre- and post-outcome erectile function and safety results. Cochrane Robins I was employed for the quality and bias risk. Four studies were finally included. The studies were of high quality as revealed from the quality assessment results. They were the non-randomized human-based clinical trials. Patients follow-up ranged from 3 to 12 months. Intercourse satisfaction scores were improved after 6 and 12 months of stem cell therapy. No serious adversities were reported during and after the study period. It was thus a safe therapeutic option as per these results. This study evaluated the role of stem cell therapy in post-RP ED. The included studies depicted its efficacy and safety. The information on stem cell therapy for ED was limited, however it could provide foundation for future research. Large-scale human studies with robust research designs would bring more objectivity and conclusive evidence.

Post-prostatectomy; Erectile dysfunction; Stem-cell therapy

[1] Capogrosso P, Salonia A, Briganti A, Montorsi F. Postprostatectomy erectile dysfunction: a review. The World Journal of Men’s Health. 2016; 34: 73.

[2] Yafi FA, Jenkins L, Albersen M, Corona G, Isidori AM, Goldfarb S, et al. Erectile dysfunction. Nature Reviews Disease Primers. 2016; 2: 16003.

[3] Tal R, Alphs HH, Krebs P, Nelson CJ, Mulhall JP. Erectile function recovery rate after radical prostatectomy: a meta-analysis. The Journal of Sexual Medicine. 2009; 6: 2538–2546.

[4] Bratu O, Oprea I, Marcu D, Spinu D, Niculae A, Geavlete B, et al. Erectile dysfunction post-radical prostatectomy—a challenge for both patient and physician. Journal of Medicine and Life. 2017; 10: 13–18.

[5] Wani MM, Rai BP, Webb WR, Madaan S. Is there a role for stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials. Therapeutic Advances in Urology. 2022; 14: 175628722210869.

[6] Mangır N, Türkeri L. Stem cell therapies in post-prostatectomy erectile dysfunction: a critical review. The Canadian Journal of Urology. 2017; 24: 8609–8619.

[7] Asker H, Yilmaz‐Oral D, Oztekin CV, Gur S. An update on the current status and future prospects of erectile dysfunction following radical prostatectomy. The Prostate. 2022; 82: 1135–1161.

[8] Protogerou V, Chrysikos D, Karampelias V, Spanidis Y, Sara EB, Troupis T. Erectile dysfunction treatment using stem cells: a review. Medicines. 2021; 8: 2.

[9] Xu P, Wang YH. Prevention and treatment of erectile dysfunction after prostatectomy: an update. National Journal of Andrology. 2017; 23: 656–662. (In Chinese)

[10] Siregar S, Novesar AR, Mustafa A. Application of stem cell in human erectile dysfunction—a systematic review. Research and Reports in Urology. 2022; 14: 379–388.

[11] Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. The BMJ. 2016; 355: i4919.

[12] Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. European Urology. 2016; 69: 988–991.

[13] Yiou R, Hamidou L, Birebent B, Bitari D, Le Corvoisier P, Contremoulins I, et al. Intracavernous injections of bone marrow mononucleated cells for postradical prostatectomy erectile dysfunction: final results of the INSTIN clinical trial. European Urology Focus. 2017; 3: 643–645.

[14] Haahr MK, Harken Jensen C, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, et al. A 12-month follow-up after a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. Urology. 2018; 121: 203.e6–203.e13.

[15] Haahr MK, Jensen CH, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016; 5: 204–210.

[16] Hansen ST, Lund M, Ostergaard LD, Lund L. Role of regenerative therapies on erectile dysfunction after radical prostatectomy. International Journal of Impotence Research. 2021; 33: 488–496.

[17] Yiou R. Stem-cell therapy for erectile dysfunction. Bio-Medical Materials and Engineering. 2017; 28: S81–S85.

[18] Pérez-Aizpurua X, Garranzo-Ibarrola M, Simón-Rodríguez C, García-Cardoso JV, Chávez-Roa C, López-Martín L, et al. Stem cell therapy for erectile dysfunction: a step towards a future treatment. Life. 2023; 13: 502.

[19] Vakalopoulos I, Memmos D, Mykoniatis I, Toutziaris C, Dimitriadis G. Stem cell therapy in erectile dysfunction: science fiction or realistic treatment option? Hormones. 2018; 17: 315–320.

[20] Gur S, Abdel-Mageed AB, Sikka SC, Hellstrom WJG. Advances in stem cell therapy for erectile dysfunction. Expert Opinion on Biological Therapy. 2018; 18: 1137–1150.

[21] Albersen M, Weyne E, Bivalacqua TJ. Stem cell therapy for erectile dysfunction: progress and future directions. Sexual Medicine Reviews. 2013; 1: 50–64.